• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Vas, where are you?

























Yammer and Vas are both the same - functionally irrelevant to driving business - just a place to spew “party line” “woke” “liberal politics” as a cover/distraction for multiple failures
 




I hope they tell us FLIPT will not be our “insurance” next year. It has added stress and confusion to employees that should be focused on patients. We can drive 30 miles to save on one drug and 20 to save on another, etc
 












I hope they tell us FLIPT will not be our “insurance” next year. It has added stress and confusion to employees that should be focused on patients. We can drive 30 miles to save on one drug and 20 to save on another, etc

Flipt sucks but its the least of your concerns. The flamethrower is coming out next week and its going to be merciless.
 








Y’all are over interpreting the situation. The lawyers have him bound up while the chopping plan is finalized. Too many legal risks to be out and about communicating right now. The Board loves Vas and will give him another go.
 





























Or Vas will announce a Megamerger, he delt with the last months. What about Amgen? Share price has been increasing since January 22, despite having a comparable business performance like Novartis.